ERBB2 and gastric cancer: Per the 2024 CSCO Gastric Cancer Guidelines (9), first-line treatment for metastatic HER2-negative gastric cancer with PD-L1 CPS ≥5 recommends XELOX (capecitabine + oxaliplatin) combined with sintilimab.